Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Astellas
Pharma
Apellis stock price slid 10% despite 'robust' growth of Syfovre
Despite the expansion of Syfovre in geographic atrophy ahead of analysts' expectations, Apellis' stock price has dropped 30% so far this year.
Angus Liu
May 8, 2024 11:30am
Ono-Deciphera, Novartis-PeptiDream, WuXi Bio—Fierce Pharma Asia
May 3, 2024 7:20am
EU regulator signs off on Novo's weekly insulin and other meds
Mar 22, 2024 11:39am
BIO-WuXi, Takeda, FDA-Carvykti—Fierce Pharma Asia
Mar 15, 2024 10:15am
The top 10 drugs losing US exclusivity in 2024
Mar 11, 2024 3:00am
Apellis working through continued challenges with Syfovre launch
Feb 28, 2024 11:53am